<DOC>
	<DOCNO>NCT02522221</DOCNO>
	<brief_summary>TACT `` real world '' randomize control trial tecarfarin , novel vitamin K antagonist , vs. warfarin . The quality anticoagulation control compare two group subject require chronic oral anticoagulation broad panel indication .</brief_summary>
	<brief_title>Tecarfarin Anti-Coagulation Trial ( TACT )</brief_title>
	<detailed_description>3000 subject indications chronic anticoagulation randomize either tecarfarin warfarin least one year ( 6 month VTE subject ) . The study fully enrich least 1200 subject mechanical heart valve primary indication chronic anticoagulation . The remain 1800 subject require take chronic medication concomitantly know interact CYP2C9 . The primary endpoint comparison Time Therapeutic Range ( TTR ) nest , blind population subject take chronic medication know interact CYP2C9 CYP2C9 genetic variant allele .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion Criteria 1 . Age &gt; 18 . 2 . Meets least one follow criterion : MHV take CYP2C9interacting medication chronically time randomization . 3 . Requires chronic anticoagulation therapy . 4 . Has one follow indication chronic oral anticoagulation : Atrial fibrillation/flutter Aortic and/or mitral prosthetic HV History chronic venous thromboembolic ( VTE ) disease acute VTE History myocardial infarction cardiomyopathy Any indication , Sponsor approval 1 . Is pregnant , nursing , woman childbearing potential assure become pregnant duration study . 2 . Has treat investigational drug within 30 day 5 halflives prior randomization , whichever longer . 3 . Has life expectancy &lt; 1 year . 4 . Is &gt; 85 year old . 5 . Has severe endorgan disease , : Estimated GFR ( eGFR ) &lt; 30 mL/min Screening per central laboratory Advanced pulmonary disease require home oxygen NYHA class IV heart failure Severe psychiatric disorder advance dementia 6 . Has history nondisabling ischemic stroke history intracranial bleeding . 7 . Alcohol substance abuse within 1 year 8 . Has anemia ( screen hemoglobin &lt; 10 g/dL ) . 9 . Has thrombocytopenia ( screen platelet count &lt; 90,000/microL ) . 10 . Has history presence illness condition , , judgment Investigator , may compromise safety subject Study Drug administration . 11 . Has know active bleeding know history lesion risk bleed gastric ulceration , colonic cerebral arteriovenous malformation , cerebral aortic aneurysm , pericarditis , endocarditis . 12 . Except MHV replacement surgery relate concurrent procedure , recently ( &lt; 14 day Screening ) undergone nonthromboembolic surgery invasive procedure lumbar puncture . 13 . Has history blood dyscrasia inherit disorder hemostasis . 14 . Has history hemorrhagic tendency prior serious hemorrhagic event hemorrhage within cranium , eye , spinal cord , retroperitoneum . 15 . Has active gross hematuria gastrointestinal bleed history condition within past 6 month prior Screening . 16 . Has receive concomitant therapy anticoagulant , antiplatelet agent , nonsteroidal antiinflammatory drug ( NSAIDs ) discontinue prior initiate tecarfarin/warfarin dosing , unless use drug necessary part bridging/transitioning first several day Study Drug administration . Daily use 81 100 mg aspirin intermittent chronic use selective COX2 inhibitor allow . 17 . Has know congenital acquire coagulation factor inhibitor present would interfere use INR ( e.g. , antiphospholipid antibody syndrome positive lupus anticoagulant ) . 18 . Has abnormally prolong prothrombin time , absence therapeutic anticoagulation , due endogenous inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>chronic anticoagulation</keyword>
	<keyword>vitamin K antagonist</keyword>
	<keyword>mechanical heart valve</keyword>
	<keyword>CYP2C9</keyword>
	<keyword>warfarin</keyword>
	<keyword>tecarfarin</keyword>
</DOC>